Estimating direct and indirect costs of premenstrual syndrome

Journal of Occupational and Environmental Medicine

Volumn 47, Issue 1, 2005, Pages 26-33

  Borenstein, Jeff ^a   Chiou, Chiun Fang ^b   Dean, Bonnie ^b,d   Wong, John ^b,c   Wade, Sally ^b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Cerner Health Insights   (United States)

^c PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

^d Health Services Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ADULT; ARTICLE; CALCULATION; ECONOMIC ASPECT; EMPLOYER; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; PREMENSTRUAL SYNDROME; PRODUCTIVITY; REGRESSION ANALYSIS; SELF REPORT;

ABSENTEEISM; ADOLESCENT; ADULT; AMBULATORY CARE; CALIFORNIA; CAPITATION FEE; FEE SCHEDULES; FEMALE; HUMANS; INSURANCE CLAIM REPORTING; MEDICARE; MIDDLE AGED; OCCUPATIONAL DISEASES; PREMENSTRUAL SYNDROME;

EID: 12344335514     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000150209.44312.d1     Document Type: Article

References (44)

1. Korzekwa MI, Steiner M. Premenstrual syndromes. Clin Obstet Gynecol. 1997;40:564-576.
2. Pearlstein T, Stone AB. Premenstrual syndrome. Psychiatr Clin North Am. 1998;21:577-590.
3. Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment- seeking behavior: experience from the United States, United Kingdom, and France. J Womens Health Gend Based Med. 1999;8:1043-1052.
4. Johnson SR. The epidemiology and social impact of premenstrual symptoms. Clin Obstet Gynecol. 1987;30:367-376.
5. Campbell EM, Peterkin D, O'Grady K, Sanson-Fisher R. Premenstrual symptoms in general practice patients. Prevalence and treatment. J Reprod Med. 1997;42:637-646.
6. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med. 1999;8:122-128.
7. Robinson RL, Swindle RW. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. J Womens Health Gend Based Med. 2000;9:757-768.
8. Ramcharan S, Love EJ, Fick GH, Goldfien A. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol. 1992;45:377-392.
9. Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry. 1990;147:1634-1636.
10. Koopmanschap MA, Rutten FF. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics. 1993;4:446-454.
11. Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Health Care Financ Rev. 1985;7:61-80.
12. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990;264:2524-2528.
13. Conti DJ, Burton WN. The economic impact of depression in a workplace. J Occup Med. 1994;36:983-988.
14. Greenberg PE, Finkelstein SN, Berndt ER. Calculating the workplace cost of chronic disease. Bus Health. 1995;13:27-8, 30.
15. Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol. 1995;95:1097-1110.
16. Rizzo JA, Abbott TA III, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ. 1996;5:249-265.
17. Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med. 1997;39:320-327.
18. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280:1490-1496.
19. Warshaw LJ, Burton WN. Cutting the costs of migraine: role of the employee health unit. J Occup Environ Med. 1998;40:943-953.
20. Bertera RL. The effects of behavioral risks on absenteeism and health-care costs in the workplace. J Occup Med. 1991;33:1119-1124.
21. Smith KJ, Everly JS Jr, Haight GT. An empirical analysis of the impact of a corporate health promotion intervention on reported sick leave absenteeism. Benefits Q. 1990;6:37-45.
22. Wood EA, Olmstead EW, Craig JL. An evaluation of lifestyle risk factors and absenteeism after two years in a worksite health promotion program. Am J Health Promot. 1989;4:128-133.
23. Yen LT, Edington DW, Witting P. Prediction of prospective medical claims and absenteeism costs for 1284 hourly workers from a manufacturing company. J Occup Med. 1992;34:428-435.
24. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The role of health risk factors and disease on worker productivity. J Occup Environ Med. 1999;41:863-877.
25. Koopman C, Pelletier KR, Murray JF, et al. Stanford presenteeism scale: health status and employee productivity. J Occup Environ Med. 2002;44:14-20.
26. Berndt ER, Finkelstein SN, Greenberg PE, et al. Workplace performance effects from chronic depression and its treatment. J Health Econ. 1998;17:511-535.
27. Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med. 1998;158:1013-1018.
28. Chirban JT, Jacobs RJ, Warren J. The 36-item short form health survey (SF-36) and work productivity and impairment (WPAI) questionnaire in panic disorder. Disease Manage Health Outcomes. 1997;1:154-164.
29. Edlund MJ, Swann AC. The economic and social costs of panic disorder. Hosp Community Psychiatry. 1987;38:1277-1279, 1288.
30. Jacobs RJ, Davidson JR, Gupta S, Meyerhoff AS. The effects of clonazepam on quality of life and work productivity in panic disorder. Am J Manag Care. 1997;3:1187-1196.
31. Jhingran P, Cady RK, Rubino J, et al. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract. 1996;42:36-42.
32. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
33. Borenstein JE, Dean BB, Endicott J, et al. The health and economic impact of premenstrual syndrome. J Reprod Med. 2003;48.
34. Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult: criterion validity of the 10-item Center for Epidemiological Studies Depression Scale (CES-D). Arch Intern Med. 1999;159:1701-1704.
35. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
36. Endicott J, Harrison W. Daily Rating of Severity of Problems Form. New York: Department of Research Assessment and Training, New York State Psychiatric Institute; 1990.
37. Current Procedural Terminology (CPT). Chicago: American Medical Association; 1999.
38. Health Care Financing Administration. 1999 Medicare Fee Schedule. Available at: http://www.hcfa.gov/stats/. Accessed March 2001.
39. US Department of Labor, Bureau of Labor Statistics. Highlights of Women's Earnings in 2000, Report 952; 2001.
40. Dean BB, Aguilar D, Crawley JA, Dubois RW. Impact of gastroesophageal reflux disease on worker productivity in an employed US population. Digestive Disease Week, May 17, 2003.
41. Henke CJ, Levin TR, Henning JM, Potter LP. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol. 2000;95:788-792.
42. Wahlqvist P. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life. Am J Gastroenterol. 2001;96:S57-S61.
43. Chiou CF, Wilson A, Longstreth G, et al. The relationship between irritable bowel syndrome abdominal discomfort/pain and indirect costs. Digestive Disease Week, May 19, 2002.
44. Roca CA, Schmidt PJ, Rubinow DR. A follow-up study of premenstrual syndrome. J Clin Psychiatry. 1999;60:763-766.